Publications
- 2019
-
-
Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors.
Mol Ther Methods Clin Dev. 2019 Mar 16;13:371-379. doi: 10.1016/j.omtm.2019.03.003. eCollection 2019 Jun 14.
-
Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors.
Front Oncol 2019 Feb 14;9:52. doi: 10.3389/fonc.2019.00052. eCollection 2019.
-
Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors.
- 2018
-
-
In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
EMBO Mol Med Sep 17 [Epub ahead of print]
-
In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
- 2017
-
-
Refining strategies to translate genome editing to the clinic
Nature Medicine 23, 415–423 (2017) doi:10.1038/nm.4313
-
Therapeutic genome editing with engineered nucleases
Hamostaseologie. 2017 Jan 31;37(1):45-52. doi: 10.5482/HAMO-16-09-0035
-
Clinical development of CAR-T cells – challenges and opportunities in translating innovative treatment concepts.
EMBO Mol Med Aug 01
-
Genome and Epigenome Editing to Treat Disorders of the Hematopoietic System
Human Gene Therapy, Volume 28, pp 1105-1115; doi:10.1089/hum.2017.149
-
Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use
Human Gene Therapy, Volume: 28 Issue 10: October 1, 2017
-
Refining strategies to translate genome editing to the clinic
- 2015
-
-
Towards a commercial process for the manufacture of genetically modified T cells for therapy
Cancer Gene Ther. 2015, Jan 23. doi: 10.1038/cgt.2014.78
-
Towards a commercial process for the manufacture of genetically modified T cells for therapy
- 2014
-
-
Engineered T cells for cancer treatment
Cytotherapy 2014; 16(6): 713-33.
-
Engineered T cells for cancer treatment